Podcast
Questions and Answers
What is the recommended frequency for monitoring in patients with active rheumatoid arthritis?
What is the recommended frequency for monitoring in patients with active rheumatoid arthritis?
- Every 2-4 months
- Every 6-12 months
- Every 3-6 months
- Every 1-3 months (correct)
What should be considered if the treatment target is not achieved with the first conventional synthetic disease-modifying antirheumatic drug (csDMARD) strategy?
What should be considered if the treatment target is not achieved with the first conventional synthetic disease-modifying antirheumatic drug (csDMARD) strategy?
- Add a biological DMARD (bDMARD) without further evaluation
- Continue with the same csDMARD at a higher dose
- Add a JAK-inhibitor immediately
- Switch to a different csDMARD without considering poor prognostic factors (correct)
What is the first-line treatment if a patient has a contraindication to methotrexate?
What is the first-line treatment if a patient has a contraindication to methotrexate?
- Leflunomide (correct)
- Hydroxychloroquine
- Anakinra
- Tocilizumab
When should short-term glucocorticoids be tapered and discontinued in the treatment of rheumatoid arthritis?
When should short-term glucocorticoids be tapered and discontinued in the treatment of rheumatoid arthritis?
What is the recommended course of action if a biological disease-modifying antirheumatic drug (bDMARD) has failed in a patient?
What is the recommended course of action if a biological disease-modifying antirheumatic drug (bDMARD) has failed in a patient?
In patients who cannot use conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) as comedication, what may be advantageous compared to other bDMARDs?
In patients who cannot use conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) as comedication, what may be advantageous compared to other bDMARDs?
What should be considered after glucocorticoids have been discontinued and a patient is in sustained remission?
What should be considered after glucocorticoids have been discontinued and a patient is in sustained remission?
What should be considered when the treatment target is not achieved with the first csDMARD strategy and poor prognostic factors are present?
What should be considered when the treatment target is not achieved with the first csDMARD strategy and poor prognostic factors are present?
What is the recommended action if there is no improvement in disease activity within 3 months of starting treatment for rheumatoid arthritis?
What is the recommended action if there is no improvement in disease activity within 3 months of starting treatment for rheumatoid arthritis?
In patients with a contraindication to methotrexate, what alternative therapy may be considered?
In patients with a contraindication to methotrexate, what alternative therapy may be considered?
When should short-term glucocorticoids be tapered and discontinued in the treatment of rheumatoid arthritis?
When should short-term glucocorticoids be tapered and discontinued in the treatment of rheumatoid arthritis?
What is part of the first treatment strategy for rheumatoid arthritis according to recommendations?
What is part of the first treatment strategy for rheumatoid arthritis according to recommendations?
In patients who cannot use conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) as comedication, what is mentioned as having potential advantages over other biological disease-modifying antirheumatic drugs?
In patients who cannot use conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) as comedication, what is mentioned as having potential advantages over other biological disease-modifying antirheumatic drugs?
After glucocorticoids have been discontinued and a patient is in sustained remission, what can be considered for dose reduction according to the text?
After glucocorticoids have been discontinued and a patient is in sustained remission, what can be considered for dose reduction according to the text?
What is recommended if a biological disease-modifying antirheumatic drug (bDMARD) or a targeted synthetic disease-modifying antirheumatic drug (tsDMARD) has failed according to the text?
What is recommended if a biological disease-modifying antirheumatic drug (bDMARD) or a targeted synthetic disease-modifying antirheumatic drug (tsDMARD) has failed according to the text?
If a patient has failed treatment with one TNF inhibitor, what is recommended in terms of subsequent treatment according to the text?
If a patient has failed treatment with one TNF inhibitor, what is recommended in terms of subsequent treatment according to the text?
When considering treatment options after treatment failure with IL-6 receptor inhibitor therapy, what is recommended according to the text?
When considering treatment options after treatment failure with IL-6 receptor inhibitor therapy, what is recommended according to the text?
